Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Juan C. Ramos, Joseph A. Sparano, Michelle A. Rudek, Page C. Moore, Ethel Cesarman, Erin G. Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y. Lee, Richard F. Ambinder, Ronald Mitsuyasu, Ariela Noy Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Prednisone | Rituxan | Study